Among the therapeutic implications of this classification, for example, SCLC subtypes with high levels of the YAP protein expressed other genes involved in immune checkpoints and changes in the tumor microenvironment towards an ‘inflamed’ type that is associated with immunotherapy sensitivity. The gene discussed is YAP1; the disease is small cell lung carcinoma.